Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy
/in Acute Leukemia, International PublicationsDendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses
/in Acute Leukemia, International PublicationsFeasibility of clinical dendritic cell vaccination in acute myeloid leukemia
/in Acute Leukemia, International PublicationsCurrent progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia
/in Acute Leukemia, International PublicationsImmunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts
/in Acute Leukemia, International PublicationsDendritic cell-based immunotherapy for the treatment of hematological malignancies
/in Acute Leukemia, Dendritic Cells, International Publications, Multiple MyelomaHyperthermic enhancement of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) cytotoxicity in human leukemia cells in vitro
/in Acute Leukemia, International PublicationsA proposal for the addition of hyperthermia to treatment regimens for acute and chronic leukemia
/in Acute Leukemia, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer